{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000153","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.362972+00:00","generated_at":"2026-05-16T17:40:08.515788+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant CMO Michael Geffner departs; consulting through April 2026","bullets":["Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.","Departure is part of R&D leadership restructuring under CEO Eric Venker.","Severance per existing employment agreement; consulting services through April 30, 2026.","Outstanding equity awards continue vesting during consulting period; accelerated vesting on change in control.","Option exercise period extended to nine months after consulting ends or original expiration, whichever earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000153","json":"https://secwatch.observer/filing/0001764013-25-000153.json","markdown":"https://secwatch.observer/filing/0001764013-25-000153.md","text":"https://secwatch.observer/filing/0001764013-25-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/0001764013-25-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/imvt-20251121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:40:08.515788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}